549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 t... von Paller, Amy, Cork, Michael, Hong, Chih-ho, Soong, Weily, Schneider, Shannon, Lo, Hannah, Pedersen, Line Rosendahl Meldgaard, Vacko, Emilia, Wollenberg, Andreas

Volltext

Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks von Wollenberg, Andreas, Cork, Michael, Hong, Chih-Ho, Kurbasic, Azra, Vacko, Emilia, Paller, Amy

Volltext

Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial von Paller, Amy, Cork, Michael, Hong, Chih-ho, Soong, Weilly, Schneider, Shannon, Lo, Hannah, Pedersen, Line Rosendahl Meldgaard, Vacko, Emilia, Wollenberg, Andreas

Volltext

3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis von Warren, Richard, Reich, Kristian, Simpson, Eric, Langley, Richard, Costanzo, Antonio, Saeki, Hidehisa, Almgren, Peter, Vacko, Emilia, Carlsson, Anna, Gooderham, Melinda, Deleuran, Mette, Silvestre, Juan Francisco, Weidinger, Stefan, Blauvelt, Andrew

Volltext

3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis von Warren, Richard B, Reich, Kristian, Simpson, Eric L, Langley, Richard, Costanzo, Antonio, Saeki, Hidehisa, Almgren, Peter, Vacko, Emilia, Gooderham, Melinda, Deleuran, Mette, Francisco Silvestre, Juan, Weidinger, Stefan, Blauvelt, Andrew

Volltext